Category: Osteoporosis
Osteoporosis market research reports by Inkwood Research
-
Zilosul Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Zilosul Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 ZILOSUL, also known as pentosan polysulfate sodium (PPS), is a semi-synthetic medication derived from the wood chips of European beech trees. The extraction process yields glucurono-xylans, which are then sulfated to crea ... Read More
-
X0002 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
X0002 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 X0002, also known as ibuprofenamine hydrochloride spray, is an innovative transdermal non-steroidal anti-inflammatory drug (NSAID) currently under clinical development for the treatment of osteoarthritis (OA) and rheumatoid ... Read More
-
Wegovy Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Wegovy Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 WEGOVY (Semaglutide) is a synthetic version of the human glucagon-like peptide-1 (GLP-1) hormone. It promotes weight loss by decreasing appetite, enhancing feelings of fullness, reducing food consumption, and lowering calo ... Read More
-
Tlc599 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Tlc599 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 TLC599 is a proprietary formulation of dexamethasone sodium phosphate (DSP) utilizing the BioSeizer technology, designed to deliver up to 24 weeks of continuous pain relief. TLC599 offers the benefit of locally delivering ... Read More
-
Sprifermin Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Sprifermin Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 Sprifermin (AS-902330) is a recombinant version of human fibroblast growth factor 18 (FGF18). Sprifermin acts as a strong agonist for FGFR2 and FGFR3 receptors. It is administered through injections directly into the j ... Read More
-
Rtx-grt7039 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Rtx-grt7039 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 RTX-GRT7039 (resiniferatoxin) is an investigational drug designed for pain relief in patients with knee osteoarthritis (OA). This highly potent agonist of the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor ... Read More
-
Renu Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Renu Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 ReNu is a cryopreserved amniotic suspension allograft (ASA) containing micronized amniotic membrane and amniotic fluid cells. The amniotic membrane serves a protective function, surrounding the fetus and acting as a barrier ... Read More
-
Mm-ii Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Mm-ii Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 MM-II is a new non-opioid intra-articular injection designed to alleviate knee pain in patients with osteoarthritis. This treatment utilizes the unique characteristics of proprietary multilamellar liposomes alongside an inn ... Read More
-
Lorecivivint Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Lorecivivint Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 Lorecivivint (SM04690) is a small-molecule inhibitor targeting the Wnt pathway, delivered through intra-articular injection, and is being explored as a potential disease-modifying osteoarthritis drug (DMOAD). Preclin ... Read More
-
Lna043 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Lna043 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 LNA043 is an innovative ANGPTL3 (angiopoietin-like 3) agonist designed to specifically target and repair damaged cartilage while influencing multiple pathways involved in cartilage regeneration. This drug is being explored ... Read More
-
Jta-004 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Jta-004 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 JTA-004 is an innovative treatment in development for managing knee osteoarthritis pain through intra-articular injections. This advanced osteoarthritis (OA) medicine features a proprietary blend of hyaluronic acid and pl ... Read More
-
Invossa Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Invossa Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 INVOSSA is a groundbreaking cell and gene therapy designed to treat knee osteoarthritis with a single intra-articular injection. Clinical trials conducted in the United States and globally have demonstrated that INVOSSA c ... Read More
-
Elixcyte Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Elixcyte Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 ELIXCYTE is an allogeneic stem cell product derived from adipose tissue, designed to regulate the immune system, reduce inflammation, and promote chondrocyte proliferation while supporting the normal function of damaged ... Read More
-
Cntx-4975 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Cntx-4975 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 CNTX-4975 is currently being evaluated as a treatment for moderate to severe knee osteoarthritis (OA) pain. It is a highly purified, synthetic form of trans-capsaicin administered via injection directly to the pain site ... Read More
-
Amz001 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Amz001 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 AMZ001 is a new topical gel formulation of diclofenac, developed specifically to treat knee osteoarthritis (OA) pain. With a high-strength concentration of 3.06% diclofenac sodium, AMZ001 stands out in the osteoarthritis m ... Read More
Research Assistance
